2024
Using in vivo intact structure for system-wide quantitative analysis of changes in proteins
Son A, Kim H, Diedrich J, Bamberger C, McClatchy D, Lipton S, Yates J. Using in vivo intact structure for system-wide quantitative analysis of changes in proteins. Nature Communications 2024, 15: 9310. PMID: 39468068, PMCID: PMC11519357, DOI: 10.1038/s41467-024-53582-x.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseProtein footprinting methodGlobal expression profilingIn vivo conformationStructural alterations of proteinsCo-expressed proteinsMass spectrometry-based methodsAlterations of proteinsProteostasis dysfunctionSpectrometry-based methodsProtein misfoldingConformation of proteinsStructural changesLysine residuesDynamic structural changesBiological functionsProteomics experimentsDimethyl labelingExpression profilesProtein conformationConformational changesProteinIntact proteinDesign of therapeutic interventionsMeasuring dynamic structural changes
2023
Restorative effect of NitroSynapsin on synaptic plasticity in an animal model of depression
Tse W, Pochwat B, Szewczyk B, Misztak P, Bobula B, Tokarski K, Worch R, Czarnota-Bojarska M, Lipton S, Zaręba-Kozioł M, Bijata M, Wlodarczyk J. Restorative effect of NitroSynapsin on synaptic plasticity in an animal model of depression. Neuropharmacology 2023, 241: 109729. PMID: 37797736, DOI: 10.1016/j.neuropharm.2023.109729.Peer-Reviewed Original ResearchConceptsMedial prefrontal cortexLong-term potentiationChronic restraint stress mouse modelSynaptic plasticityN-methyl-D-aspartate receptor antagonistRestraint stress mouse modelMale C57BL/6J miceAntidepressant-like activityTail suspension testStress mouse modelFunctional synaptic plasticityMajor depressive disorderAntidepressant potentialPharmacological treatmentPsychotomimetic effectsReceptor antagonistC57BL/6J miceDepressive behaviorSucrose preferenceDepressive disorderNitroSynapsinMouse modelSuspension testBehavioral disturbancesCerebrocortical neurons
2014
Cognitive deficits associated with combined HIV gp120 expression and chronic methamphetamine exposure in mice
Kesby J, Markou A, Semenova S, Grant I, Ellis R, Letendre S, Achim C, Woods S, Carr A, Letendre S, Ellis R, Schrier R, Heaton R, Atkinson J, Cherner M, Marcotte T, Morgan E, Brown G, Jernigan T, Dale A, Liu T, Scadeng M, Fennema-Notestine C, Archibald S, Achim C, Masliah E, Lipton S, Soontornniyomkij V, Gamst A, Cushman C, Abramson I, Vaida F, Deutsch R, Umlauf A, Atkinson J, Marquie-Beck J, Minassian A, Perry W, Geyer M, Henry B, Young J, Grethe A, Paulus M, Ellis R, Morris S, Smith D, Grant I, Semenova S, Markou A, Kesby J, Kaul M. Cognitive deficits associated with combined HIV gp120 expression and chronic methamphetamine exposure in mice. European Neuropsychopharmacology 2014, 25: 141-150. PMID: 25476577, PMCID: PMC4289653, DOI: 10.1016/j.euroneuro.2014.07.014.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, OcularAnalysis of VarianceAnimalsBody WeightCentral Nervous System StimulantsCognition DisordersDisease Models, AnimalGene Expression RegulationGlial Fibrillary Acidic ProteinHIV Envelope Protein gp120MaleMaze LearningMethamphetamineMiceMice, Inbred C57BLMice, TransgenicReaction TimeRecognition, PsychologyConceptsGp120-tg miceCognitive domainsBarnes mazeMethamphetamine exposureCognitive deficitsSpatial learningAssociative recognition memoryDiscrete cognitive domainsMethamphetamine abuseHuman immunodeficiency virusRecognition memoryExecutive functionBarnes maze testCognitive performanceChronic methamphetamine exposureCognitive functionGp120 expressionAcquisition trialsGreater deficitsHIV infectionPlace testStrategy scoresNeurocognitive outcomesMethamphetamine usersSpatial strategies
2001
Is tissue plasminogen activator a threat to neurons?
Traynelis S, Lipton S. Is tissue plasminogen activator a threat to neurons? Nature Medicine 2001, 7: 17-18. PMID: 11135603, DOI: 10.1038/83289.Peer-Reviewed Original Research
1999
Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat
Stieg P, Sathi S, Warach S, Le D, Lipton S. Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat. European Journal Of Pharmacology 1999, 375: 115-120. PMID: 10443569, DOI: 10.1016/s0014-2999(99)00214-9.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingSide effectsInfarct sizeNeonatal ratsChannel blockersNMDA receptorsFocal cerebral ischemia modelNeurobehavioral side effectsIschemic brain injuryEffects of memantineExcitatory amino acidsInduction of strokeRodent stroke modelsAdult animal modelsCerebral ischemia modelSubstantial side effectsCerebral focal ischemiaNumerous side effectsNeuronal cell culturesNeonatal neuronsPhotochemical thrombosisPhotothrombotic modelNeuronal injuryCerebral ischemiaFocal ischemia
1998
Tissue plasminogen activator (tPA) increase neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice
Wang Y, Tsirka S, Strickland S, Stieg P, Soriano S, Lipton S. Tissue plasminogen activator (tPA) increase neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nature Medicine 1998, 4: 228-231. PMID: 9461198, DOI: 10.1038/nm0298-228.Peer-Reviewed Original ResearchConceptsTissue plasminogen activatorTPA-deficient miceWild-type miceCerebral infarctsNeuronal damageEffects of tPAIntravenous tissue plasminogen activatorRole of tPAPlasminogen activatorSmall cerebral infarctsAcute cerebral infarctsFocal cerebral ischemiaMiddle cerebral arteryIschemia/reperfusionStroke-induced injuryCerebral viabilityIntravascular filamentAcute strokeExcitotoxic damageCerebral ischemiaCerebral arteryLarge infarctsIntracerebral injectionIntravenous injectionThrombolytic agents
1996
Elevated Glutamate Levels in the Vitreous Body of Humans and Monkeys With Glaucoma
Dreyer E, Zurakowski D, Schumer R, Podos S, Lipton S. Elevated Glutamate Levels in the Vitreous Body of Humans and Monkeys With Glaucoma. JAMA Ophthalmology 1996, 114: 299-305. PMID: 8600890, DOI: 10.1001/archopht.1996.01100130295012.Peer-Reviewed Original ResearchConceptsExcitatory amino acid glutamateRetinal ganglion cellsAmino acid glutamateVitreous bodyGlaucomatous eyesGanglion cellsGlutamate levelsRetinal ganglion cell neuronsOptic nerve damageGroup of patientsElevated glutamate levelsGanglion cell neuronsLevels of glutamateEyes of monkeysNerve damageControl eyesVisual dysfunctionNonglaucomatous eyesCataract extractionPosterior capsuleInadvertent ruptureDisease processGlaucomaCell neuronsPatients
1995
gp120 and neurotoxicity in vivo Consideration of animal models and technical methods in interpretation of negative data
Lipton S, Brenneman D, Silverstein F, Masliah E, Mucke L. gp120 and neurotoxicity in vivo Consideration of animal models and technical methods in interpretation of negative data. Trends In Pharmacological Sciences 1995, 16: 122. PMID: 7610496, DOI: 10.1016/s0165-6147(00)88998-1.Peer-Reviewed Original Research